Seeking Alpha EN

Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M

Mar 12, 2026 &03141212202631; 19:14 UTC seekingalpha.com Trending 4/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -45/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Century Therapeutics reported a GAAP loss per share of -$0.14 with revenue of $109.2M, indicating continued operating losses despite revenue generation. This suggests the company is still in a growth/investment phase with negative profitability metrics.

AI CONFIDENCE

72% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

CTRY

CTRYStock

Expected to decline

Negative EPS of -$0.14 indicates ongoing losses and cash burn despite revenue generation, likely to pressure stock price in near term

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor Century Therapeutics for path to profitability and cash runway. Consider shorting or avoiding until company demonstrates positive EPS or significant revenue acceleration. Watch for pipeline progress announcements that could justify current valuation.

KEY SIGNALS

Negative GAAP EPSRevenue of $109.2M shows business activity but insufficient to cover operating expensesCompany remains unprofitableTypical biotech development stage metrics

SECTORS INVOLVED

HealthcareBiotechnologyPharmaceuticals

Analysis generated on Mar 16, 2026 at 16:29 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M

RELATED INTELLIGENCE